Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Blood (2017) 129 (26): 3419–3427.

https://doi.org/10.1182/blood-2017-02-765685

Published: 2017

Includes: Supplemental data

Journal Articles

Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes

Sameer A. Parikh, MD, Kari G Chaffee, MS, Timothy G. Call, MD, Jose F. Leis, MD, PhD, Wei Ding, MD PhD, Saad S Kenderian, MD, Asher A. Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael J Conte, PA-C, Susan M. Schwager, Susan L. Slager, PhD, Curtis A. Hanson, MD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2016) 128 (22): 3228.

https://doi.org/10.1182/blood.V128.22.3228.3228

Published: 2016

Journal Articles

The Role of Splenectomy in the Care and Treatment of the CLL Patient

Michael J Conte, PA-C, Sameer A. Parikh, MD, Deborah A. Bowen, APRN, CNP, Timothy G. Call, MD, Brian F Kabat, Kari G Chaffee, MS, Susan M. Schwager, Susan L. Slager, PhD, Wei Ding, MD PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2016) 128 (22): 5575.

https://doi.org/10.1182/blood.V128.22.5575.5575

Published: 2016

Journal Articles

Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort

Paul J Hampel, MD, Kari G. Chaffee, MS, Simonetto A Douglas, MD, Timothy G. Call, MD, Wei Ding, MD PhD, Saad S Kenderian, MD, Jose F. Leis, MD, PhD, Asher A. Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael J Conte, PA-C, Sara J Achenbach, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2016) 128 (22): 5585.

https://doi.org/10.1182/blood.V128.22.5585.5585

Published: 2016

Journal Articles

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Blood (2016) 128 (22): 4392.

https://doi.org/10.1182/blood.V128.22.4392.4392

Published: 2016

Journal Articles

Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes

Mazie Tsang, MD, Kari Rabe Chaffee, MS, Timothy G. Call, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Asher Chanan-Khan, MD, Michael Conte, PA-C, Deborah A. Bowen, APRN, CNP, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2015) 126 (23): 4169.

https://doi.org/10.1182/blood.V126.23.4169.4169

Published: 2015

Journal Articles

The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice

Heidi D. Finnes, PharmD, Kari G. Chaffee, MS, Timothy G. Call, MD, Wei Ding, MD PhD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Kristen B. McCullough, PharmD, Julianna A. Merten, PharmD, Gabriel T. Bartoo, PharmD, Matthew D. Smith, PharmD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2015) 126 (23): 717.

https://doi.org/10.1182/blood.V126.23.717.717

Published: 2015

Journal Articles

Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia

Wei Ding, MD PhD, Sara J Achenbach, Kari G. Chaffee, MS, Timothy G. Call, MD, Sameer A. Parikh, MD, Susan M. Schwager, Jose F. Leis, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Susan L. Slager, PhD, Kay Medina, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2015) 126 (23): 2926.

https://doi.org/10.1182/blood.V126.23.2926.2926

Published: 2015

Journal Articles

Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice

Sameer A. Parikh, MD, Kari Rabe Chaffee, MS, Timothy G. Call, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Daniel L. Van Dyke, PhD, Curtis A. Hanson, MD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2015) 126 (23): 2935.

https://doi.org/10.1182/blood.V126.23.2935.2935

Published: 2015

Journal Articles

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Wei Ding, MD PhD, Haidong Dong, MD PhD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Betsy R. Laplant, MS, Rong He, MD, Thomas E. Witzig, MD, Yi Lin, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Thomas M. Habermann, MD, David Viswanatha, MD, Ivana Micallef, MD, Neil E. Kay, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 834.

https://doi.org/10.1182/blood.V126.23.834.834

Published: 2015

Journal Articles

Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial

Clive S. Zent, MD, Betsy R. LaPlant, Timothy G. Call, MD, Deborah A. Bowen, Michael J. Conte, PA-C, Wei Ding, MD, PhD, George J. Weiner, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 1792.

https://doi.org/10.1182/blood.V120.21.1792.1792

Published: 2012

Journal Articles

Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,

Tait D. Shanafelt, MD, Mark C Lanasa, MD, PhD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Timothy G Call, MD, Betsy R. LaPlant, Han Tun, MD, Deborah A. Bowen, Diane F. Jelinek, Ph.D., Curtis A. Hanson, MD, Neil Kay, MD

Blood (2011) 118 (21): 3898.

https://doi.org/10.1182/blood.V118.21.3898.3898

Published: 2011

Journal Articles

Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,

Jonathan Moreira, MD, Kari Rabe, MS, James R Cerhan, MD, PhD, Curtis A. Hanson, MD, Timothy G Call, MD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Deborah A. Bowen, John Wilson, MD, Neil Kay, MD, Susan Schwager, Randy F Wendt, Susan L Slager, PhD, Tait D. Shanafelt, MD

Blood (2011) 118 (21): 3903.

https://doi.org/10.1182/blood.V118.21.3903.3903

Published: 2011

Journal Articles

Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)

Clive S. Zent, MD, Betsy R. LaPlant, Brian K Link, MD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Deborah A. Bowen, Neil Kay, MD, George J. Weiner, MD, Thomas E. Witzig, MD

Blood (2011) 118 (21): 1790.

https://doi.org/10.1182/blood.V118.21.1790.1790

Published: 2011

Journal Articles

Melanoma and Non-Melanoma Skin Cancer in Patients with Chronic Lymphocytic Leukemia.

Timothy G Call, MD, Kari G Rabe, MS, Brewer D Jerry, M.D., Neil E. Kay, MD, Clive S. Zent, MD, Susan M Schwager, Deborah A Bowen, FNP, Jose F Leis, MD, Han Tun, MD, Svetomir N Markovic, MD, PhD, Susan L Slager, PhD, Tait D. Shanafelt, M.D.

Blood (2009) 114 (22): 1268.

https://doi.org/10.1182/blood.V114.22.1268.1268

Published: 2009

Journal Articles

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Clive S. Zent, MD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, Charla R. Secreto, Deborah A. Bowen, RN, Susan M. Geyer, PhD, Brian F. Kabat, Betsy R. LaPlant, Wenting Wu, PhD, Neil E. Kay, MR

Blood (2007) 110 (11): 2050.

https://doi.org/10.1182/blood.V110.11.2050.2050

Published: 2007

Journal Articles

The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).

Clive S. Zent, MD, Wei Ding, MD, PhD, Karin F. Giordano, MD, Susan M. Schwager, Tait D. Shanafelt, MD, Megan S. Reinalda, James D. Hoyer, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, Deborah A. Bowen, RN, Timothy G. Call, MD, Neil E. Kay, MD, Susan L. Slager, PhD

Blood (2007) 110 (11): 746.

https://doi.org/10.1182/blood.V110.11.746.746

Published: 2007

Journal Articles

The Prognostic Importance of T and NK-Cells in a Consecutive Series of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia.

Shanique Palmer, Curtis A. Hanson, MD, Clive S. Zent, MD, Louis F. Porrata, MD, Betsy LaPlant, Susan M. Geyer, PhD, Svetomir N. Markovic, MD/PhD, Timothy G. Call, MD, Deborah A. Bowen, Diane F. Jelinek, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2007) 110 (11): 3080.

https://doi.org/10.1182/blood.V110.11.3080.3080

Published: 2007

NARROW

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes

The Role of Splenectomy in the Care and Treatment of the CLL Patient

Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes

The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice

Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia

Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial

Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,

Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,

Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)

Melanoma and Non-Melanoma Skin Cancer in Patients with Chronic Lymphocytic Leukemia.

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).

The Prognostic Importance of T and NK-Cells in a Consecutive Series of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only